Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Under the Healthcare Common Procedure Coding System (HCPCS), the Q-code Q9999 is for “Injection, for subcutaneous use or intravenous use, ustekinumab-aauz (Otulfi), biosimilar per 1.0 mg.” ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the report finds.

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE <li /> Q1 2025 net sal ...

South Korea’s Samsung Bioepis today released its Second Quarter 2025 Biosimilar Market Report, which provides the second ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

Sabre Corporation ("Sabre") will host a live webcast of its first quarter 2025 earnings conference call on May 7, 2025 at 9:00 a.m. ET. Management will discuss the financial results, as well as ...

Honeywell today announced that its Board of Directors has declared a quarterly dividend payment of $1.13 per share on the Company's common stock. The dividend is payable on June 6, 2025, out of ...

J&J's older IL-23 drug Stelara (ustekinumab) is also approved for Crohn's and remains a big seller, making upwards of $10 billion across multiple indications. However, it has been outperformed in ...